Compare CRNX & ANF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CRNX | ANF |
|---|---|---|
| Founded | 2008 | 1892 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Clothing/Shoe/Accessory Stores |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.9B | 3.9B |
| IPO Year | 2018 | 1996 |
| Metric | CRNX | ANF |
|---|---|---|
| Price | $42.21 | $91.71 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 8 | 12 |
| Target Price | $76.75 | ★ $120.50 |
| AVG Volume (30 Days) | ★ 1.3M | 1.2M |
| Earning Date | 05-07-2026 | 05-27-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ 1.47 |
| Revenue | $1,039,000.00 | ★ $5,266,292,000.00 |
| Revenue This Year | $720.10 | $5.10 |
| Revenue Next Year | $184.67 | $3.83 |
| P/E Ratio | ★ N/A | $62.86 |
| Revenue Growth | N/A | ★ 6.42 |
| 52 Week Low | $25.83 | $65.45 |
| 52 Week High | $57.99 | $133.11 |
| Indicator | CRNX | ANF |
|---|---|---|
| Relative Strength Index (RSI) | 71.81 | 62.22 |
| Support Level | $38.68 | $91.48 |
| Resistance Level | $44.89 | $93.47 |
| Average True Range (ATR) | 1.71 | 3.87 |
| MACD | 0.74 | 0.48 |
| Stochastic Oscillator | 97.89 | 77.88 |
Crinetics Pharmaceuticals Inc is a commercial-stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. Its main product, Palsonify (paltusotine), is a once-daily, oral treatment approved by the FDA for adults with acromegaly who have had an inadequate response to surgery and/or for whom surgery is not an option. Additionally, the company's development pipeline includes several programs, including a late-stage investigational candidate, atumelnant, currently in development for CAH and ADCS, and CRN09682, a NDC candidate that is being developed to treat SST2-expressing NETs and other SST2-expressing solid tumors.
Abercrombie & Fitch Co is a digitally led, omnichannel retailer offering apparel, personal care products, and accessories for men, women, and kids through company-owned stores, digital channels, and third-party arrangements. The company operates through three geographic segments: Americas, the maximum revenue generator; Europe, the Middle East and Africa (EMEA); and Asia-Pacific (APAC). Its brand families include Abercrombie brands and Hollister brands. The Americas segment covers North and South America, EMEA includes Europe, the Middle East and Africa, and APAC includes the Asia-Pacific region, including Asia and Oceania.